Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Deals Drug

Huadong Medicine’s HDM2024 Wins FDA Phase I Approval – First-in-Class EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors

Fineline Cube Mar 12, 2026
Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Fineline Cube Mar 11, 2026
Company Deals Drug

AstraZeneca Initiates CLARITY-Gastric 02 Phase III – Sonesitatug Vedotin Combo Triggers $45 Million Milestone from KYM Biosciences

Fineline Cube Mar 11, 2026
Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Boehringer Ingelheim’s Jascayd (Nerandomilast) Launches in Shanghai – First PDE4B Inhibitor for Idiopathic Pulmonary Fibrosis

Fineline Cube Mar 12, 2026
Deals Drug

Huadong Medicine’s HDM2024 Wins FDA Phase I Approval – First-in-Class EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors

Fineline Cube Mar 12, 2026
Company

Newdel Biotech Secures A+ Round Funding to Accelerate DEL+AI-Driven Drug Discovery

Fineline Cube Mar 12, 2025

Newdel Biotech recently announced the completion of an A+ round strategic investment led by XtalPi...

Company Deals

Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases

Fineline Cube Mar 12, 2025

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has formed a partnership with compatriot...

Company Deals

Merck Sharp & Dohme Expands Durham Facility with $1B Investment for Vaccine Production

Fineline Cube Mar 12, 2025

US-based giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the opening of a...

Company Drug

Novartis’ Cosentyx Approved by NMPA for Moderate to Severe Hidradenitis Suppurativa

Fineline Cube Mar 12, 2025

Swiss giant Novartis’ (NYSE: NVS) Cosentyx (secukinumab) has secured another indication approval from China’s National...

Company

Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results

Fineline Cube Mar 12, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting...

Company Deals

Ono Pharmaceutical Licenses Ionis’ Sapablursen for Global Development in Polycythemia Vera

Fineline Cube Mar 12, 2025

Japan-based Ono Pharmaceutical Co., Ltd. (TYO: 4528) announced an agreement with Ionis Pharmaceuticals, Inc. to...

Company Deals

Boehringer Ingelheim Launches One Medicine Platform with Veeva’s Development Cloud

Fineline Cube Mar 12, 2025

German pharmaceutical giant Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) announced the successful launch of...

Company Drug

Biogen Initiates TRANSCEND Study for Felzartamab in Late AMR Kidney Transplant Patients

Fineline Cube Mar 12, 2025

US-based Biogen Inc. (NASDAQ: BIIB) announced the initiation of the TRANSCEND study, a global Phase...

Company Deals

MindRank Ltd Receives FDA Clearance for MRANK-106 Clinical Study in Solid Tumors

Fineline Cube Mar 12, 2025

China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced receiving clearance from the US Food...

Company Drug

AIM Vaccine Co. Ltd Announces Market Filing for Innovative Serum-Free Rabies Vaccine

Fineline Cube Mar 12, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) announced plans to file for market approval for...

Company Deals

TowardPi Medical Secures RMB500 Million in Series E Round for Ophthalmic Equipment Expansion

Fineline Cube Mar 12, 2025

China-based TowardPi (Beijing) Medical Technology Ltd, a leading ophthalmology equipment R&D company, has reportedly secured...

Company Deals

WuXi XDC and AbTis Partner to Advance Antibody-Drug Conjugate Innovation

Fineline Cube Mar 12, 2025

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA...

Company Drug

Ascletis Pharma’s ASC47 Shows Positive Results in Phase Ib Study for Weight Loss

Fineline Cube Mar 12, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced positive topline results from a Phase Ib clinical...

Company Drug

AstraZeneca’s Imfinzi Approved by NMPA for Early-Stage NSCLC Treatment

Fineline Cube Mar 11, 2025

UK-based giant AstraZeneca (NASDAQ: AZN) received approval from China’s National Medical Products Administration (NMPA) for...

Company Medical Device

Huihe Healthcare’s K-Clip Wins Chinese Approval for Tricuspid Regurgitation Treatment

Fineline Cube Mar 11, 2025

Shanghai-based Huihe Healthcare, a developer of structural heart disease intervention medical devices, announced receiving marketing...

Company

Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth

Fineline Cube Mar 11, 2025

China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy...

Company Deals

Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out

Fineline Cube Mar 11, 2025

Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ)...

Company Drug

Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Wins New NMPA Approval for NSCLC

Fineline Cube Mar 11, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced receiving another indication approval from the...

Company

Illumina Responds to Chinese MOFCOM Notice Amid Sequencing Instrument Export Ban

Fineline Cube Mar 11, 2025

US major Illumina (NASDAQ: ILMN), which was included in a list of unreliable entities issued...

Company Drug

Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment

Fineline Cube Mar 11, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to...

Posts pagination

1 … 165 166 167 … 633

Recent updates

  • Boehringer Ingelheim’s Jascayd (Nerandomilast) Launches in Shanghai – First PDE4B Inhibitor for Idiopathic Pulmonary Fibrosis
  • Huadong Medicine’s HDM2024 Wins FDA Phase I Approval – First-in-Class EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors
  • Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029
  • J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer
  • Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Boehringer Ingelheim’s Jascayd (Nerandomilast) Launches in Shanghai – First PDE4B Inhibitor for Idiopathic Pulmonary Fibrosis

Deals Drug

Huadong Medicine’s HDM2024 Wins FDA Phase I Approval – First-in-Class EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.